In a phase II trial testing salirasib, among the 33 patients with advanced lung adenocarcinoma enrolled, 30 showed tumors harboring KRAS mutations (23 previously treated patients and 7 treatment-naïve individuals) [92]. Here, KRAS is linked to lung adenocarcinoma.